• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Experience With the Wearable Cardioverter-Defibrillator in Patients at High Risk for Sudden Cardiac Death.可穿戴式心脏复律除颤器在心脏性猝死高危患者中的应用经验
Circulation. 2016 Aug 30;134(9):635-43. doi: 10.1161/CIRCULATIONAHA.115.019124. Epub 2016 Jul 25.
2
Protection from outpatient sudden cardiac death following ICD removal using a wearable cardioverter defibrillator.使用可穿戴式心脏复律除颤器移除植入式心脏复律除颤器（ICD）后预防门诊患者心源性猝死
Pacing Clin Electrophysiol. 2014 May;37(5):562-8. doi: 10.1111/pace.12319. Epub 2013 Dec 3.
3
Use of the wearable cardioverter defibrillator in high-risk cardiac patients: data from the Prospective Registry of Patients Using the Wearable Cardioverter Defibrillator (WEARIT-II Registry).可穿戴式心脏除颤器在高危心脏患者中的应用：来自前瞻性可穿戴式心脏除颤器（WEARIT-II 注册研究）患者使用登记数据库的数据。
Circulation. 2015 Oct 27;132(17):1613-9. doi: 10.1161/CIRCULATIONAHA.115.015677. Epub 2015 Aug 27.
4
The US Experience of the Wearable Cardioverter-Defibrillator in Pediatric Patients.美国小儿患者应用可穿戴式心脏除颤器的经验。
Circ Arrhythm Electrophysiol. 2018 Jul;11(7):e006163. doi: 10.1161/CIRCEP.117.006163.
5
Utility of the Wearable Cardioverter-Defibrillator in Patients With Newly Diagnosed Cardiomyopathy: A Decade-Long Single-Center Experience.新式心肌病患者佩戴式除颤器的实用性：长达十年的单中心经验。
J Am Coll Cardiol. 2015 Dec 15;66(23):2607-2613. doi: 10.1016/j.jacc.2015.09.079.
6
Management of sudden cardiac death in cardiac sarcoidosis using the wearable cardioverter defibrillator.使用可穿戴式除颤器管理心脏结节病中的心脏性猝死。
PLoS One. 2018 Mar 22;13(3):e0194496. doi: 10.1371/journal.pone.0194496. eCollection 2018.
7
National experience with long-term use of the wearable cardioverter defibrillator in patients with cardiomyopathy.心肌病患者长期使用可穿戴式心脏复律除颤器的国家经验。
J Interv Card Electrophysiol. 2017 Jan;48(1):11-19. doi: 10.1007/s10840-016-0194-6. Epub 2016 Oct 17.
8
Experience with the wearable cardioverter-defibrillator in older patients: Results from the Prospective Registry of Patients Using the Wearable Cardioverter-Defibrillator.老年患者穿戴式除颤器的应用经验：来自穿戴式除颤器患者前瞻性注册研究的结果。
Heart Rhythm. 2018 Sep;15(9):1379-1386. doi: 10.1016/j.hrthm.2018.04.014. Epub 2018 Apr 18.
9
Ventricular arrhythmias in patients with newly diagnosed nonischemic cardiomyopathy: Insights from the PROLONG study.新诊断的非缺血性心肌病患者的室性心律失常：来自PROLONG研究的见解。
Clin Cardiol. 2017 Aug;40(8):586-590. doi: 10.1002/clc.22706. Epub 2017 Mar 23.
10
Wearable cardioverter-defibrillator in patients with a transient risk of sudden cardiac death: the WEARIT-France cohort study.可穿戴式心脏除颤器在有短暂性心源性猝死风险患者中的应用：WEARIT-France 队列研究。
Europace. 2021 Jan 27;23(1):73-81. doi: 10.1093/europace/euaa268.

引用本文的文献

1
Role of the wearable cardioverter defibrillator in the initial period of sudden cardiac death risk stratification: results of a European Heart Rhythm Association survey.可穿戴式心脏复律除颤器在心脏性猝死风险分层初期的作用：欧洲心律协会调查结果
Europace. 2025 Jul 1;27(7). doi: 10.1093/europace/euaf118.
2
Cost-Utility Analysis of LifeVest® in Post-Myocardial Infarction Patients at Risk of Sudden Cardiac Death in England.英国心肌梗死后有心脏性猝死风险患者使用LifeVest®的成本效用分析。
Pharmacoecon Open. 2025 Mar;9(2):301-312. doi: 10.1007/s41669-024-00553-z. Epub 2025 Jan 24.
3
False Alarms in Wearable Cardioverter Defibrillators-A Relevant Issue or an Insignificant Observation.可穿戴式心脏复律除颤器中的误报——一个相关问题还是微不足道的观察结果。
J Clin Med. 2024 Dec 19;13(24):7768. doi: 10.3390/jcm13247768.
4
Wearable Cardioverter Defibrillator as a Treatment in Patients with Heart Failure of Various Aetiologies-A Series of Ten Cases Within the BIA-VEST Registry.可穿戴式心脏复律除颤器在各种病因所致心力衰竭患者中的治疗应用——BIA-VEST注册研究中的十例病例系列
J Clin Med. 2024 Dec 17;13(24):7686. doi: 10.3390/jcm13247686.
5
Wearable defibrillator to improve accuracy in selecting candidates to implantable defibrillator: A real-world experience.可穿戴式除颤器提高植入式除颤器候选者选择的准确性：一项真实世界经验。
ESC Heart Fail. 2024 Dec;11(6):3993-3999. doi: 10.1002/ehf2.14840. Epub 2024 Aug 1.
6
Sex differences in achieving guideline-recommended heart rate control among a large sample of patients at risk for sudden cardiac arrest.在大量有心脏骤停风险的患者样本中，实现指南推荐的心率控制方面的性别差异。
Heart Rhythm O2. 2024 Apr 15;5(5):274-280. doi: 10.1016/j.hroo.2024.04.008. eCollection 2024 May.
7
[History of the implantable cardioverter-defibrillator in Germany].[德国植入式心脏复律除颤器的历史]
Herzschrittmacherther Elektrophysiol. 2024 Mar;35(Suppl 1):55-67. doi: 10.1007/s00399-024-01001-5. Epub 2024 Feb 29.
8
The Role of the Wearable Defibrillator in Heart Failure.可穿戴除颤器在心力衰竭中的作用。
Curr Heart Fail Rep. 2024 Feb;21(1):33-42. doi: 10.1007/s11897-023-00641-x. Epub 2024 Jan 18.
9
Use of the Wearable Cardioverter-Defibrillator Among Patients With Myocarditis and Reduced Ejection Fraction or Ventricular Tachyarrhythmia: Data From a Multicenter Registry. wearable 除颤器在心梗伴射血分数降低或室性心律失常患者中的应用：多中心注册研究数据
J Am Heart Assoc. 2023 Sep 19;12(18):e030615. doi: 10.1161/JAHA.123.030615. Epub 2023 Sep 8.
10
..
Int J Cardiol Heart Vasc. 2023 Aug 30;48:101258. doi: 10.1016/j.ijcha.2023.101258. eCollection 2023 Oct.

本文引用的文献

1
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC).2015年欧洲心脏病学会（ESC）室性心律失常患者管理和心脏性猝死预防指南：欧洲心脏病学会（ESC）室性心律失常患者管理和心脏性猝死预防工作组得到欧洲儿科和先天性心脏病学会（AEPC）认可。
Europace. 2015 Nov;17(11):1601-87. doi: 10.1093/europace/euv319. Epub 2015 Aug 29.
2
Use of the wearable cardioverter defibrillator in high-risk cardiac patients: data from the Prospective Registry of Patients Using the Wearable Cardioverter Defibrillator (WEARIT-II Registry).可穿戴式心脏除颤器在高危心脏患者中的应用：来自前瞻性可穿戴式心脏除颤器（WEARIT-II 注册研究）患者使用登记数据库的数据。
Circulation. 2015 Oct 27;132(17):1613-9. doi: 10.1161/CIRCULATIONAHA.115.015677. Epub 2015 Aug 27.
3
Wearable cardioverter-defibrillator use in patients perceived to be at high risk early post-myocardial infarction.穿戴式心脏除颤器在心肌梗死后早期被认为高危患者中的应用。
J Am Coll Cardiol. 2013 Nov 19;62(21):2000-2007. doi: 10.1016/j.jacc.2013.05.086. Epub 2013 Jul 31.
4
Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator.植入式心脏复律除颤器治疗的风险分层：可穿戴式心脏除颤器的作用。
Eur Heart J. 2013 Aug;34(29):2230-42. doi: 10.1093/eurheartj/eht167. Epub 2013 May 31.
5
Early risk of mortality after coronary artery revascularization in patients with left ventricular dysfunction and potential role of the wearable cardioverter defibrillator.左心室功能障碍患者冠状动脉血运重建术后的早期死亡率风险及可穿戴式除颤器的潜在作用。
Circ Arrhythm Electrophysiol. 2013 Feb;6(1):117-28. doi: 10.1161/CIRCEP.112.973552. Epub 2012 Dec 28.
6
Reduction in inappropriate therapy and mortality through ICD programming.通过 ICD 编程减少不适当的治疗和死亡率。
N Engl J Med. 2012 Dec 13;367(24):2275-83. doi: 10.1056/NEJMoa1211107. Epub 2012 Nov 6.
7
The natural history of new-onset heart failure with a severely depressed left ventricular ejection fraction: implications for timing of implantable cardioverter-defibrillator implantation.新发心力衰竭伴严重左心室射血分数降低患者的自然病史：对植入式心脏复律除颤器植入时机的影响。
Am Heart J. 2012 Sep;164(3):358-64. doi: 10.1016/j.ahj.2012.06.009.
8
Chest compression-only CPR by lay rescuers and survival from out-of-hospital cardiac arrest.急救员行单纯胸外按压心肺复苏术和院外心脏骤停患者的生存
JAMA. 2010 Oct 6;304(13):1447-54. doi: 10.1001/jama.2010.1392.
9
Aggregate national experience with the wearable cardioverter-defibrillator: event rates, compliance, and survival.可穿戴式除颤器的综合国家经验：事件发生率、依从性和生存率。
J Am Coll Cardiol. 2010 Jul 13;56(3):194-203. doi: 10.1016/j.jacc.2010.04.016.
10
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons.《美国心脏病学会/美国心脏协会/心律学会2008年心脏节律异常器械治疗指南》：美国心脏病学会/美国心脏协会实践指南工作组（修订ACC/AHA/NASPE 2002年心脏起搏器和抗心律失常器械植入指南更新的写作委员会）报告：与美国胸外科协会和胸外科医师学会合作制定。
Circulation. 2008 May 27;117(21):e350-408. doi: 10.1161/CIRCUALTIONAHA.108.189742. Epub 2008 May 15.

可穿戴式心脏复律除颤器在心脏性猝死高危患者中的应用经验

Experience With the Wearable Cardioverter-Defibrillator in Patients at High Risk for Sudden Cardiac Death.

作者信息

Wäßnig Nadine K, Günther Michael, Quick Silvio, Pfluecke Christian, Rottstädt Fabian, Szymkiewicz Steven J, Ringquist Steven, Strasser Ruth H, Speiser Uwe

机构信息

From Technische Universität Dresden, Heart Center Dresden, University Hospital, Department of Internal Medicine and Cardiology, Dresden, Germany (N.W., M.G., S.Q., C.P., F.R., R.S., U.S.); and ZOLL, Pittsburgh, PA (S.S., S.R.).

出版信息

Circulation. 2016 Aug 30;134(9):635-43. doi: 10.1161/CIRCULATIONAHA.115.019124. Epub 2016 Jul 25.

DOI:10.1161/CIRCULATIONAHA.115.019124
PMID:27458236
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4998124/
Abstract

BACKGROUND

This study evaluated the wearable cardioverter-defibrillator (WCD) for use and effectiveness in preventing sudden death caused by ventricular tachyarrhythmia or fibrillation.

METHODS

From April 2010 through October 2013, 6043 German WCD patients (median age, 57 years; male, 78.5%) were recruited from 404 German centers. Deidentified German patient data were used for a retrospective, nonrandomized analysis.

RESULTS

Ninety-four patients (1.6%) were treated by the WCD in response to ventricular tachyarrhythmia/fibrillation. The incidence rate was 8.4 (95% confidence interval, 6.8-10.2) per 100 patient-years. Patients with implantable cardioverter-defibrillator explantation had an incidence rate of 19.3 (95% confidence interval, 12.2-29.0) per 100 patient-years. In contrast, an incidence rate of 8.2 (95% confidence interval, 6.4-10.3) was observed in the remaining cardiac diagnosis groups, including dilated cardiomyopathy, myocarditis, and ischemic and nonischemic cardiomyopathies. Among 120 shocked patients, 112 (93%) survived 24 hours after treatment, whereas asystole was observed in 2 patients (0.03%) with 1 resulting death.

CONCLUSIONS

This large cohort represents the first nationwide evaluation of WCD use in patients outside the US healthcare system and confirms the overall value of the WCD in German treatment pathways.

摘要

背景

本研究评估了可穿戴式心脏复律除颤器（WCD）在预防室性快速心律失常或颤动所致猝死方面的使用情况及有效性。

方法

从2010年4月至2013年10月，从德国404个中心招募了6043例德国WCD患者（中位年龄57岁；男性占78.5%）。使用经过去识别处理的德国患者数据进行回顾性非随机分析。

结果

94例患者（1.6%）接受了WCD针对室性快速心律失常/颤动的治疗。发病率为每100患者年8.4例（95%置信区间为6.8 - 10.2）。植入式心脏复律除颤器被移除的患者发病率为每100患者年19.3例（95%置信区间为12.2 - 29.0）。相比之下，在包括扩张型心肌病、心肌炎以及缺血性和非缺血性心肌病在内的其余心脏诊断组中，观察到的发病率为每100患者年8.2例（95%置信区间为6.4 - 10.3）。在120例接受电击治疗的患者中，112例（93%）在治疗后存活24小时，而2例患者（0.03%）出现心脏停搏，其中1例死亡。

结论

这个大型队列代表了对美国医疗系统以外患者使用WCD的首次全国性评估，并证实了WCD在德国治疗途径中的总体价值。